154 related articles for article (PubMed ID: 31363223)
1. Human CRISPR.
Rusk N
Nat Methods; 2019 Aug; 16(8):677. PubMed ID: 31363223
[No Abstract] [Full Text] [Related]
2. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
3. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
4. Genome editing: CRISPR-Cas becoming more human.
Baumann K
Nat Rev Mol Cell Biol; 2017 Oct; 18(10):591. PubMed ID: 28811667
[No Abstract] [Full Text] [Related]
5. CRISPR tool puts RNA on the record.
Beisel CL
Nature; 2018 Oct; 562(7727):347-349. PubMed ID: 30323226
[No Abstract] [Full Text] [Related]
6. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas in its prime.
Zlotorynski E
Nat Rev Mol Cell Biol; 2019 Dec; 20(12):718-719. PubMed ID: 31685954
[No Abstract] [Full Text] [Related]
8. Genome editing: The efficient tool CRISPR-Cpf1.
Mahfouz MM
Nat Plants; 2017 Mar; 3():17028. PubMed ID: 28260792
[No Abstract] [Full Text] [Related]
9. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
10. Pioneers of revolutionary CRISPR gene editing win chemistry Nobel.
Ledford H; Callaway E
Nature; 2020 Oct; 586(7829):346-347. PubMed ID: 33028993
[No Abstract] [Full Text] [Related]
11. Include egg donors in CRISPR gene-editing debate.
Niemiec E; Howard HC
Nature; 2019 Nov; 575(7781):51. PubMed ID: 31690864
[No Abstract] [Full Text] [Related]
12. Cas9 immunity creates challenges for CRISPR gene editing therapies.
Crudele JM; Chamberlain JS
Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-mediated gene editing to rescue haploinsufficient obesity syndrome.
Wang Z; Yang L; Qu S; Zhang C
Protein Cell; 2019 Oct; 10(10):705-708. PubMed ID: 31124015
[No Abstract] [Full Text] [Related]
14. Next-generation diagnostics with CRISPR.
Chertow DS
Science; 2018 Apr; 360(6387):381-382. PubMed ID: 29700254
[No Abstract] [Full Text] [Related]
15. The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs.
Bayat H; Omidi M; Rajabibazl M; Sabri S; Rahimpour A
J Microbiol Biotechnol; 2017 Feb; 27(2):207-218. PubMed ID: 27840399
[TBL] [Abstract][Full Text] [Related]
16. Challenges and advances of CRISPR-Cas9 genome editing in therapeutics.
Stellos K; Musunuru K
Cardiovasc Res; 2019 Feb; 115(2):e12-e14. PubMed ID: 30668679
[No Abstract] [Full Text] [Related]
17. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
Duroux-Richard I; Giovannangeli C; Apparailly F
Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
[No Abstract] [Full Text] [Related]
18. Genetic engineering: Chemical control for CRISPR editing.
Hilton IB; Gersbach CA
Nat Chem Biol; 2017 Jan; 13(1):2-3. PubMed ID: 27820804
[No Abstract] [Full Text] [Related]
19. Inhibiting CRISPR.
Rusk N
Nat Methods; 2019 Mar; 16(3):218. PubMed ID: 30814697
[No Abstract] [Full Text] [Related]
20. Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo".
Kim ST; Park J; Kim D; Kim K; Bae S; Schlesner M; Kim JS
Nat Methods; 2018 Apr; 15(4):239-240. PubMed ID: 29600990
[No Abstract] [Full Text] [Related]
[Next] [New Search]
